STRO — Sutro Biopharma Income Statement
0.000.00%
Last trade - 00:00- $92.80m
- -$224.10m
- $62.04m
Annual income statement for Sutro Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 42.7 | 61.9 | 67.8 | 154 | 62 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 114 | 160 | 197 | 243 | 300 |
| Operating Profit | -71.1 | -98.5 | -129 | -89.3 | -238 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -32.1 | -106 | -117 | -88.6 | -225 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -32.1 | -106 | -119 | -107 | -227 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -32.1 | -106 | -119 | -107 | -227 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -32.1 | -106 | -119 | -107 | -227 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.986 | -2.29 | -2.35 | -1.78 | -2.96 |